Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Lukas Biomedical's Enterprise Value is NT$1,153.5 Mil.
Lukas Biomedical's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-69.9 Mil. Therefore, Lukas Biomedical's EV-to-FCF for today is -16.49.
The historical rank and industry rank for Lukas Biomedical's EV-to-FCF or its related term are showing as below:
ROCO:6814'
s EV-to-FCF Range Over the Past 10 Years
Min: -148.9 Med: -43.21 Max: 116.84
Current: -15.86
During the past 8 years, the highest EV-to-FCF of Lukas Biomedical was 116.84. The lowest was -148.90. And the median was -43.21.
ROCO:6814's EV-to-FCF is ranked worse than 100% of 336
companies
in the Biotechnology industry
Industry Median: 15.16
vs ROCO:6814: -15.86
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Lukas Biomedical's PE Ratio (TTM) for today is calculated as:
Lukas Biomedical's share price for today is NT$24.65.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Lukas Biomedical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-2.050.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Lukas Biomedical EV-to-FCF Related Terms
Lukas Biomedical EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Lukas Biomedical's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6814 vs VRTX, REGN, ALNY: EV-to-FCF Comparison
For the Biotechnology subindustry, Lukas Biomedical's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lukas Biomedical EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lukas Biomedical's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Lukas Biomedical's EV-to-FCF falls into.
Lukas Biomedical's current Enterprise Value is NT$1,153.5 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Lukas Biomedical's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-69.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lukas Biomedical (ROCO:6814) has a EV-to-FCF of -16.49 as of Jul. 21, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Lukas Biomedical and its competitors. According to the industry distribution chart, Lukas Biomedical ranks #999999 out of 336 companies in the Biotechnology industry.
Is Lukas Biomedical's EV-to-FCF too high?
Lukas Biomedical's current EV-to-FCF is -16.49. Based on the distribution chart, Lukas Biomedical ranks #999999 out of 336 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Lukas Biomedical has a GF Score™ of 66/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lukas Biomedical's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Lukas Biomedical ranks #999999 out of 336 companies for EV-to-FCF. This places Lukas Biomedical in the lower half of its industry. The industry median EV-to-FCF is 15.16. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 15.16, based on 336 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Lukas Biomedical and its competitors. For the Biotechnology industry, the median EV-to-FCF is 15.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lukas Biomedical's current EV-to-FCF is -16.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lukas Biomedical stock overvalued right now?
Based on GuruFocus' analysis, Lukas Biomedical (ROCO:6814) is currently considered Modestly Overvalued. The stock's GF Value™ is NT$21.77, compared to a current price of NT$24.65 — trading 13.2% above its estimated fair value. The current EV-to-FCF is -16.49. Lukas Biomedical's overall GF Score™ is 66/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Lukas Biomedical (ROCO:6814), the current EV-to-FCF is -16.49 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lukas Biomedical (ROCO:6814) Overvalued in 2026?
Based on GuruFocus' analysis, Lukas Biomedical stock appears to be overvalued.
The current stock price of NT$24.65 is trading 13.2% above its estimated GF Value™ of NT$21.77.
GuruFocus considers Lukas Biomedical to be Modestly Overvalued.
Key valuation signals for ROCO:6814:
EV-to-FCF: -16.49
GF Value™: NT$21.77 vs. price of NT$24.65 (13.2% above fair value)
No single metric tells the full story. See the ROCO:6814 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lukas Biomedical Inc. is engaged in researching and developing immunotherapy for cancer treatment technologies. The company's main business activities include developing immunocellular therapy, leasing and selling medical equipment, and selling biotech beauty products.
66GF Score
Get the complete analysis for ROCO:6814
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6814 has been successfully added to your 
